Acinetobacter baumannii

Acinetobacter baumannii is a bacterium most people have never heard of, yet in the world of hospital medicine it is one of the most feared names there is. It rarely troubles healthy people going about their lives. Instead, it thrives in intensive care units, on ventilators, and in the wounds of the seriously ill — and it has become extraordinarily good at shrugging off the antibiotics we count on. The World Health Organization ranks carbapenem-resistant Acinetobacter as a critical-priority pathogen: a bug so hard to treat that developing new drugs against it is considered an urgent global need. This page explains, in plain language, what the organism is, the infections it causes, who is truly at risk, why it is so difficult to kill, and — most usefully — how hospitals and families can help stop it from spreading. The honest bottom line up front: for the general public the risk is low, but for a critically ill patient this can be a life-threatening, sometimes barely treatable infection, and prevention matters more than any single drug.

Overview
The Bacterium: A Hardy Survivor
The Infections It Causes
Who's Most at Risk
Diagnosis
The Antibiotic-Resistance Problem
Treatment: The Drugs That Still Work
Prevention and Infection Control
The Bottom Line
Research Papers
Connections
Featured Videos

Overview

Acinetobacter baumannii is a Gram-negative bacterium that, over the past few decades, has become one of the most notorious causes of hospital-acquired (nosocomial) infection. It is not a common community germ like the ones behind sore throats or ordinary food poisoning. Its home is the healthcare environment, and its victims are almost always people who are already very sick — patients in intensive care, on breathing machines, recovering from major trauma or burns, or with lines and tubes that give bacteria a doorway into the body.

What sets A. baumannii apart is the combination of two dangerous traits. First, it is remarkably tough in the environment, surviving for weeks on dry surfaces and medical equipment, which lets it move from patient to patient across a ward. Second, and more alarmingly, it is a champion of antibiotic resistance. Many strains are resistant to nearly every drug we have, and a growing number are resistant to all of them. Because of this, the WHO placed carbapenem-resistant Acinetobacter at the very top of its 2017 list of pathogens for which new antibiotics are most urgently needed.

The good news, if there is any, is that this is a problem of hospitals and the critically ill, not of everyday life. Understanding it is less about protecting yourself in the community and more about understanding how modern hospitals fight to keep the sickest patients safe — and why infection control and careful antibiotic use are the real weapons against it.

The Bacterium: A Hardy Survivor

Acinetobacter baumannii is a Gram-negative coccobacillus — a short, plump rod that looks halfway between a sphere and a rod under the microscope. Its genus name comes from the Greek akinetos, meaning “non-motile,” because unlike many bacteria it has no whip-like tails to swim with. It does not need to swim, though, because its real talent is staying put and staying alive.

Most Gram-negative bacteria dry out and die quickly outside a moist host. A. baumannii does the opposite: it tolerates desiccation, a wide range of temperatures, and many common disinfectants far better than its relatives. Laboratory studies have shown it can survive on dry surfaces for weeks — sometimes months. That single property is a big reason it spreads in hospitals: it lingers on bed rails, blood-pressure cuffs, ventilator tubing, keyboards, sinks, and the hands of staff, waiting for the next vulnerable patient. It also readily forms biofilms — slimy protective communities — on plastic catheters and tubes, where it is shielded from both antibiotics and the immune system.

In the laboratory, clinicians often refer to the closely related group of species as the Acinetobacter baumannii–calcoaceticus complex, because a few near-identical species are difficult to tell apart and behave similarly in patients. A. baumannii itself is the one that causes the great majority of serious human disease.

The “Iraqibacter” nickname

During the wars in Iraq and Afghanistan, military hospitals saw a striking rise in multidrug-resistant Acinetobacter infections in wounded soldiers. The organism turned up in blast wounds, fractures, and bloodstream infections among troops evacuated through the military medical system, earning it the grim battlefield nickname “Iraqibacter.” Investigations traced much of the spread not to the desert soil itself but to contamination within the field hospitals and the evacuation chain — a vivid reminder that this is above all a bug of healthcare settings, wherever they happen to be.

The Infections It Causes

Acinetobacter baumannii is an opportunist: it seldom causes disease in healthy tissue, but when a critically ill patient's defenses are down and a tube or wound offers a way in, it can cause severe, invasive infection. The main forms are:

Ventilator-associated pneumonia (VAP). This is the classic and most common serious Acinetobacter infection. In patients breathing through a tube in the windpipe, the bacterium can colonize the airway and then invade the lungs, causing a pneumonia that is difficult to treat and carries a high death rate — though partly because these patients are so sick to begin with.
Bloodstream infections and sepsis. Central venous catheters (“central lines”) and other invasive devices can let the organism reach the blood, triggering sepsis — a body-wide, life-threatening reaction to infection.
Wound and burn infections. Traumatic wounds, surgical sites, and especially large burns provide raw, exposed tissue that Acinetobacter readily colonizes and invades. This is the setting behind many military and disaster-related outbreaks.
Urinary tract infections. These are usually linked to urinary catheters left in place for long periods, common in hospitalized and ICU patients.
Meningitis. Less commonly, A. baumannii can infect the fluid and membranes around the brain, typically after neurosurgery or in patients with external ventricular drains — a serious, hard-to-treat complication.

An important and honest caveat: A. baumannii frequently just colonizes patients — living on the skin or in the airway without causing harm. Telling true infection apart from harmless colonization is one of the real challenges in caring for these patients, and it shapes decisions about when antibiotics are truly needed.

Who's Most at Risk

The people who develop serious Acinetobacter infections share a recognizable profile. The strongest risk factors are:

Being in an intensive care unit (ICU). The single biggest risk factor. The sickest patients, the most invasive devices, and the heaviest antibiotic use all come together in the ICU.
Mechanical ventilation. A breathing tube bypasses the body's natural airway defenses and is the direct route to ventilator-associated pneumonia.
Central lines and other invasive devices. Catheters in veins, the bladder, or the brain's ventricles each create a pathway for bacteria to bypass the skin.
Serious burns, major trauma, or recent surgery. Large areas of damaged or exposed tissue are prime territory for colonization and invasion.
Long hospital stays. The longer a patient is in the hospital, the more chances there are to encounter and be colonized by the organism.
Recent broad-spectrum antibiotics. Powerful antibiotics — especially carbapenems and third-generation cephalosporins — wipe out competing bacteria and clear the way for resistant Acinetobacter to take hold.
A weakened immune system. Cancer treatment, transplantation, and other immunosuppressing conditions lower the body's ability to hold the organism in check.

By contrast, healthy people living in the community are at very low risk. Community-acquired Acinetobacter pneumonia does occur, but it is rare and tends to be seen in specific settings, such as certain tropical regions and in people with heavy alcohol use. For the average reader, this is not a germ to lose sleep over — it is a germ to understand.

Diagnosis

Diagnosing Acinetobacter infection rests on culturing the organism from the site that is actually infected — not just from wherever it happens to be living. Depending on the clinical picture, samples may come from:

Blood, when bloodstream infection or sepsis is suspected;
Respiratory secretions (sputum, or fluid washed from deep in the lungs during a bronchoscopy) for suspected pneumonia;
Wound or tissue samples from infected surgical sites or burns;
Urine, usually in catheterized patients;
Cerebrospinal fluid (a spinal-tap sample) when meningitis is a concern.

Modern laboratories can identify the organism quickly and accurately using techniques such as MALDI-TOF mass spectrometry and automated systems. But identification is only half the job. Because resistance is so central to this bug, the truly essential step is antibiotic susceptibility testing — deliberately exposing the isolated bacteria to a panel of drugs to see which, if any, still work. With A. baumannii, doctors cannot safely guess at treatment; they must let the laboratory tell them what the specific strain in front of them is vulnerable to. Susceptibility results guide, and often completely change, the choice of therapy.

A recurring judgment call is deciding whether a positive culture represents a real infection that needs treating or merely colonization. The answer depends on the whole picture — fever, white-cell counts, the appearance of a wound, chest X-ray findings — not on the culture alone. Treating colonization unnecessarily only fuels more resistance.

The Antibiotic-Resistance Problem

This is the heart of why Acinetobacter baumannii is so feared, and it deserves an honest, clear-eyed account. The organism is dangerous less because of how aggressively it attacks — many patients are colonized without harm — and more because, when it does cause invasive infection, we so often have almost nothing left to treat it with.

A. baumannii is resistant to antibiotics in two ways. It is intrinsically resistant to a number of drugs from birth — its outer membrane and built-in pumps and enzymes shrug them off. On top of that, it is an extraordinary acquirer of new resistance, readily picking up resistance genes from other bacteria via mobile pieces of DNA (plasmids, transposons, and integrons). Over time, individual strains stack resistance mechanism upon resistance mechanism.

The clinical shorthand used to describe this escalation:

Multidrug-resistant (MDR) — resistant to at least one drug in three or more antibiotic classes.
Extensively drug-resistant (XDR) — resistant to nearly everything, susceptible to only one or two remaining classes.
Pan-drug-resistant (PDR) — resistant to every antibiotic tested. Rare, but real, and terrifying when it appears.

The most important resistance milestone is the loss of the carbapenems — powerful, broad, hospital-workhorse antibiotics that were long the reliable answer for serious Acinetobacter infection. Strains that defeat them are called carbapenem-resistant Acinetobacter baumannii (CRAB), usually through enzymes (especially OXA-type carbapenemases and metallo-β-lactamases) that chew the drugs up before they can work. CRAB is now common in many parts of the world, and it is CRAB specifically that the WHO flagged as a critical-priority target for new antibiotic development in 2017.

The result is a genuine global stewardship crisis. Mortality in serious CRAB infections is high — driven partly by how sick these patients already are, and partly by the simple, sobering fact that the drugs available to treat them are few, older, more toxic, and less reliable than we would like.

Treatment: The Drugs That Still Work

Because susceptibility varies so much from strain to strain, there is no single “standard” regimen for Acinetobacter. Treatment is individualized and guided entirely by laboratory testing, and specialist infectious-disease input is the norm. When the strain is still broadly susceptible, sensible β-lactam antibiotics (including carbapenems) may work well. The hard problem is CRAB, where the toolbox is small and imperfect. The main options:

Sulbactam. Best known as a partner that protects other antibiotics from being destroyed, sulbactam is unusual in having its own direct activity against Acinetobacter. Given at high doses, it is an important part of many treatment regimens.
Sulbactam-durlobactam. A newer combination developed specifically for Acinetobacter, in which durlobactam shields sulbactam from the enzymes CRAB uses to defeat it. In the phase 3 ATTACK trial it performed comparably to colistin while being notably less toxic to the kidneys — a meaningful advance for a field starved of options.
Cefiderocol. A clever “Trojan-horse” antibiotic that disguises itself as iron so the bacterium actively pulls it inside. It is active against many CRAB strains. Honesty requires a caveat: in one descriptive trial (CREDIBLE-CR), patients with Acinetobacter treated with cefiderocol had a numerically higher death rate, so it is used thoughtfully rather than as an automatic first choice.
Colistin and the polymyxins. These are old, last-line drugs revived out of necessity. They often still work against CRAB, but they can damage the kidneys and nervous system, so they are used carefully and increasingly as part of combinations or when nothing better is available.
Tetracycline-class agents such as minocycline and tigecycline, and sometimes aminoglycosides, may play a role depending on the specific susceptibility results.

Doctors frequently combine two agents in the hope of a stronger effect, though the evidence that combinations reliably save more lives than a single active drug is genuinely mixed. The overarching message is honest and humbling: for the most resistant strains, we are working with a handful of imperfect tools, and outcomes still depend heavily on early source control (removing infected lines or draining infected tissue), supportive intensive care, and getting the right drug to the right patient as quickly as testing allows.

Prevention and Infection Control

Here is the most useful part of the whole story, because prevention is where the battle against Acinetobacter is actually won or lost. Since the organism spreads within hospitals and clings to surfaces, stopping it is far more about meticulous infection control than about any wonder drug. The proven measures:

Hand hygiene. The simplest and most powerful tool. Consistent handwashing with soap and water, and use of alcohol-based hand rubs, by every staff member between every patient contact breaks the main chain of transmission.
Meticulous cleaning and disinfection. Because Acinetobacter survives for weeks on dry surfaces, thorough, repeated cleaning of the patient environment and shared equipment — monitors, cuffs, ventilators, bed rails — is essential. Some units use dedicated, single-patient equipment to avoid sharing.
Contact precautions and cohorting. Colonized or infected patients are cared for with gowns and gloves, and are often grouped together (“cohorted”) with dedicated staff and equipment so the organism cannot hitch a ride to uninfected patients.
Careful device and line care. Following strict “bundles” for inserting and maintaining central lines, urinary catheters, and ventilators — and removing them as soon as they are no longer needed — closes the doorways the bacterium exploits.
Antibiotic stewardship. Using powerful antibiotics only when genuinely necessary, and for no longer than needed, reduces the selection pressure that lets resistant Acinetobacter outcompete everything else. Stewardship is prevention in the deepest sense: it slows the very rise of resistance.
Outbreak response. When cases cluster, hospitals investigate the source, intensify cleaning, screen contacts, and occasionally close and deep-clean a unit to break the chain.

For families of a critically ill loved one, there is a small but real role to play: it is entirely reasonable to ask staff whether they have cleaned their hands, to practice good hand hygiene yourself when visiting, and to ask about how lines and catheters are being cared for. These are not signs of distrust — they are exactly the behaviors that hospital infection-control teams want to encourage.

The Bottom Line

Acinetobacter baumannii is a paradox: a germ that is almost harmless to the healthy public yet among the deadliest threats to the critically ill. It earns its fearsome reputation not through aggression but through endurance and resistance — surviving on surfaces long enough to reach the next vulnerable patient, then resisting nearly everything we throw at it. For a person in the ICU with a resistant strain, it can be a genuinely life-threatening, sometimes barely treatable infection.

But the story is not one of helplessness. The most effective defenses are unglamorous and entirely within reach: clean hands, clean equipment, careful use of tubes and lines, and disciplined antibiotic stewardship. New drugs like sulbactam-durlobactam and cefiderocol are welcome reinforcements, but they are no substitute for stopping the spread in the first place. If you are healthy and reading this, the practical takeaway is reassurance. If you have a loved one in the hospital, the practical takeaway is that infection control is real, it works, and you are allowed to be part of it.

Research Papers

Peleg AY, Seifert H, Paterson DL. Acinetobacter baumannii: emergence of a successful pathogen. Clinical Microbiology Reviews. 2008;21(3):538–582. doi:10.1128/CMR.00058-07 — The landmark review of how a once-obscure organism became a leading multidrug-resistant hospital pathogen.
Munoz-Price LS, Weinstein RA. Acinetobacter infection. New England Journal of Medicine. 2008;358(12):1271–1281. doi:10.1056/NEJMra070741 — A clinical overview of the infections A. baumannii causes and the difficulties of treating them.
Wong D, Nielsen TB, Bonomo RA, et al. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges. Clinical Microbiology Reviews. 2017;30(1):409–447. doi:10.1128/CMR.00058-16 — A comprehensive modern synthesis of epidemiology, virulence, and management.
Tacconelli E, Carrara E, Savoldi A, et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. The Lancet Infectious Diseases. 2018;18(3):318–327. doi:10.1016/S1473-3099(17)30753-3 — The analysis that ranked carbapenem-resistant Acinetobacter among the top “critical” priorities for new drugs.
Dijkshoorn L, Nemec A, Seifert H. An increasing threat in hospitals: multidrug-resistant Acinetobacter baumannii. Nature Reviews Microbiology. 2007;5(12):939–951. doi:10.1038/nrmicro1789 — Why the organism spreads so readily in hospitals and how resistance accumulates.
Harding CM, Hennon SW, Feldman MF. Uncovering the mechanisms of Acinetobacter baumannii virulence. Nature Reviews Microbiology. 2018;16(2):91–102. doi:10.1038/nrmicro.2017.148 — How the bacterium resists drying out, forms biofilms, and causes disease.
Jawad A, Seifert H, Snelling AM, Heritage J, Hawkey PM. Survival of Acinetobacter baumannii on dry surfaces: comparison of outbreak and sporadic isolates. Journal of Clinical Microbiology. 1998;36(7):1938–1941. doi:10.1128/JCM.36.7.1938-1941.1998 — A classic study measuring how long the organism survives on hospital surfaces — often weeks.
Scott P, Deye G, Srinivasan A, et al. An outbreak of multidrug-resistant Acinetobacter baumannii–calcoaceticus complex infection in the US military health care system associated with military operations in Iraq. Clinical Infectious Diseases. 2007;44(12):1577–1584. doi:10.1086/518170 — The wartime wound-infection outbreak behind the nickname “Iraqibacter.”
Isler B, Doi Y, Bonomo RA, Paterson DL. New treatment options against carbapenem-resistant Acinetobacter baumannii infections. Antimicrobial Agents and Chemotherapy. 2019;63(1):e01110-18. doi:10.1128/AAC.01110-18 — A review of the limited drug options for carbapenem-resistant strains.
Tamma PD, Aitken SL, Bonomo RA, et al. Infectious Diseases Society of America 2023 guidance on the treatment of antimicrobial-resistant Gram-negative infections. Clinical Infectious Diseases. Published online 2023. doi:10.1093/cid/ciad428 — Expert, practical treatment guidance including a dedicated section on carbapenem-resistant A. baumannii.
Kaye KS, Shorr AF, Wunderink RG, et al. Efficacy and safety of sulbactam–durlobactam versus colistin for the treatment of patients with serious infections caused by the Acinetobacter baumannii–calcoaceticus complex (ATTACK): a phase 3, randomised, non-inferiority trial. The Lancet Infectious Diseases. 2023;23(9):1072–1084. doi:10.1016/S1473-3099(23)00184-6 — The pivotal trial of the newer sulbactam–durlobactam combination built specifically for Acinetobacter.
Bassetti M, Echols R, Matsunaga Y, et al. Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a phase 3, randomised, open-label trial. The Lancet Infectious Diseases. 2021;21(2):226–240. doi:10.1016/S1473-3099(20)30796-9 — The cefiderocol trial that also flagged higher mortality signals in Acinetobacter, underscoring how hard these infections are to treat.

Back to Table of Contents

Connections